Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhifa Wang

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
British Journal of Haematology|January 5, 2025
Long-term efficacy and safety of avatrombopag in Chinese children with primary immune thrombocytopenia: A real-world observational studyNan Wang, Zhifa Wang, Jingjing Liu, et al.
International Journal of Nanomedicine|March 24, 2025
Layered Double Hydroxide Nanoparticles Loaded with Resveratrol Inhibit Glycolysis and Show Efficacy in the Treatment of Breast CancerChenchen Geng, Liuyang Yan, Yunhao Li, et al.
Journal of Thrombosis and Haemostasis : JTH|December 16, 2023
Machine learning models developed and internally validated for predicting chronicity in pediatric immune thrombocytopeniaJingyao Ma, Chang Cui, Yongqiang Tang, et al.
Research and Practice in Thrombosis and Haemostasis|April 1, 2025
Stepwise response-guided treatment protocol superior to thrombopoietin receptor agonist-based second-line therapy for severe persistent/chronic immune thrombocytopenia: a multicenter prospective study from ChinaLingling Fu, Xi Lin, Zhenping Chen, et al.
Annals of Hematology|September 11, 2025
Multicenter, real-world observational study of AVA therapy following ELT/HET switching in Chinese children with persistent/chronic primary ITPJingjing Liu, Zhifa Wang, Nan Wang, et al.
Bioorganic Chemistry|March 14, 2026
Layered double hydroxide nanoplatform synergizes with sonodynamic therapy to induce dual activation of cuproptosis and ferroptosis for breast cancer treatmentQiyu Zhu, Zhifa Wang, Lu Xia, et al.
British Journal of Haematology|February 16, 2024
Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in ChinaZhifa Wang, Aijun Zhang, Zhongjin Xu, et al.
British Journal of Haematology|July 16, 2025
Machine learning to forecast rituximab responses for paediatric immune thrombocytopenia: Forging a path towards personalized medical careJingyao Ma, Chang Cui, Juntao Ouyang, et al.
Research and Practice in Thrombosis and Haemostasis|December 11, 2025
Rituximab-first versus eltrombopag monotherapy in pediatric persistent/chronic immune refractory thrombocytopenia after first-line therapy: a prospective multicenter cohort studyJingyao Ma, Zhifa Wang, Juntao Ouyang, et al.
Annals of Hematology|June 8, 2026
Prediction of avatrombopag-induced thrombocytosis in pediatric immune thrombocytopenia: an AI-based real-world studyXi Lin, Yuntian Wang, Yunqi Zhu, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
British Journal of Haematology|January 5, 2025
Long-term efficacy and safety of avatrombopag in Chinese children with primary immune thrombocytopenia: A real-world observational studyNan Wang, Zhifa Wang, Jingjing Liu, et al.
International Journal of Nanomedicine|March 24, 2025
Layered Double Hydroxide Nanoparticles Loaded with Resveratrol Inhibit Glycolysis and Show Efficacy in the Treatment of Breast CancerChenchen Geng, Liuyang Yan, Yunhao Li, et al.
Journal of Thrombosis and Haemostasis : JTH|December 16, 2023
Machine learning models developed and internally validated for predicting chronicity in pediatric immune thrombocytopeniaJingyao Ma, Chang Cui, Yongqiang Tang, et al.
Research and Practice in Thrombosis and Haemostasis|April 1, 2025
Stepwise response-guided treatment protocol superior to thrombopoietin receptor agonist-based second-line therapy for severe persistent/chronic immune thrombocytopenia: a multicenter prospective study from ChinaLingling Fu, Xi Lin, Zhenping Chen, et al.
Annals of Hematology|September 11, 2025
Multicenter, real-world observational study of AVA therapy following ELT/HET switching in Chinese children with persistent/chronic primary ITPJingjing Liu, Zhifa Wang, Nan Wang, et al.
Bioorganic Chemistry|March 14, 2026
Layered double hydroxide nanoplatform synergizes with sonodynamic therapy to induce dual activation of cuproptosis and ferroptosis for breast cancer treatmentQiyu Zhu, Zhifa Wang, Lu Xia, et al.
British Journal of Haematology|February 16, 2024
Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in ChinaZhifa Wang, Aijun Zhang, Zhongjin Xu, et al.
British Journal of Haematology|July 16, 2025
Machine learning to forecast rituximab responses for paediatric immune thrombocytopenia: Forging a path towards personalized medical careJingyao Ma, Chang Cui, Juntao Ouyang, et al.
Research and Practice in Thrombosis and Haemostasis|December 11, 2025
Rituximab-first versus eltrombopag monotherapy in pediatric persistent/chronic immune refractory thrombocytopenia after first-line therapy: a prospective multicenter cohort studyJingyao Ma, Zhifa Wang, Juntao Ouyang, et al.
Annals of Hematology|June 8, 2026
Prediction of avatrombopag-induced thrombocytosis in pediatric immune thrombocytopenia: an AI-based real-world studyXi Lin, Yuntian Wang, Yunqi Zhu, et al.
Pageof 5